International Psoriasis Council

Advancing Knowledge. Improving Care.

Images Terms of Use

The following terms govern the use of the images provided on this site:

  1. Purpose: The images contained in this gallery are provided for educational purposes only and are not intended for clinical diagnosis or treatment.
  2. Permitted Use: Users may download and use the images solely for educational, non-commercial purposes. Any other use, including but not limited to the reproduction, distribution, display, or transmission of the content of this site, is strictly prohibited unless authorized by the International Psoriasis Council.
  3. Attribution: Users must provide appropriate credit to the International Psoriasis Council and the contributing physicians, as specified on the image pages.
  4. No Alterations: Users may not modify any images unless expressly permitted by the International Psoriasis Council.
  5. Disclaimer: International Psoriasis Council does not warrant the accuracy, completeness, or usefulness of the information available on this site. The information is provided “as is” without warranty of any kind, and the International Psoriasis Council disclaims all warranties, including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose.
  6. Limitation of Liability: The International Psoriasis Council shall not be liable for any damages whatsoever arising out of the use, inability to use, or the results of use of this site, any websites linked to this site, or the materials or information contained at any or all such sites.
  7. Revocation of Use: IPC reserves the right to revoke or modify these terms without notice.
  8. User Responsibility: Users are responsible for ensuring their use complies with applicable laws and institutional policies.

By using this site, you agree to comply with these Terms of Use. If you do not agree to these terms, do not use this site.

Effective Date: June 18, 2025

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026